Abiopharma

🔍 Mohan Jitendra (Director)

Company: Astera Labs, Inc. (ALAB)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Sold 8,754 shares of Common Stock at $125.5575 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,680,478.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 5,746 shares of Common Stock at $126.6444 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,674,732.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 3,624 shares of Common Stock at $127.4731 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,671,108.00 | transaction_form_type: 4 | Footnotes: F1, F5, F3
• Sold 7,907 shares of Common Stock at $128.6415 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,663,201.00 | transaction_form_type: 4 | Footnotes: F1, F6, F3
• Sold 11,120 shares of Common Stock at $129.6162 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,652,081.00 | transaction_form_type: 4 | Footnotes: F1, F7, F3
• Sold 13,880 shares of Common Stock at $130.741 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,638,201.00 | transaction_form_type: 4 | Footnotes: F1, F8, F3
• Sold 22,766 shares of Common Stock at $131.6101 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,615,435.00 | transaction_form_type: 4 | Footnotes: F1, F9, F3
• Sold 43,289 shares of Common Stock at $132.7214 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,572,146.00 | transaction_form_type: 4 | Footnotes: F1, F10, F3
• Sold 22,309 shares of Common Stock at $133.6642 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,549,837.00 | transaction_form_type: 4 | Footnotes: F1, F11, F3
• Sold 18,105 shares of Common Stock at $134.6738 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,531,732.00 | transaction_form_type: 4 | Footnotes: F1, F12, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-17 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 699,999.00 | Footnotes: F13
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-17 | Code: H | nature_of_ownership: By 2021 Trust 1 | shares_owned_after: 700,000.00 | Footnotes: F14
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-17 | Code: H | nature_of_ownership: By 2021 Trust 2 | shares_owned_after: 700,000.00 | Footnotes: F15
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-17 | Code: H | nature_of_ownership: By 2022 Trust 1 | shares_owned_after: 450,001.00 | Footnotes: F16
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-17 | Code: H | nature_of_ownership: By 2022 Trust 2 | shares_owned_after: 450,001.00 | Footnotes: F17
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-17 | Code: H | shares_owned_after: 1,452,739.00

Footnotes:

• F1: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2025.
• F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.0700 to $126.0000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: These shares are owned directly by a living trust (the "Living Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.0800 to $127.0600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.1100 to $128.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.1500 to $129.1300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.1600 to $130.1500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.1600 to $131.1500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.1600 to $132.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.1750 to $133.1700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F11: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.1775 to $134.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F12: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.2000 to $135.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F13: These shares are owned directly by an estate planning trust (the "Trust"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F14: These shares are owned directly by an estate planning trust (the "2021 Trust 1"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F15: These shares are owned directly by an estate planning trust (the "2021 Trust 2"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F16: These shares are owned directly by an estate planning trust (the "2022 Trust 1"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F17: These shares are owned directly by an estate planning trust (the "2022 Trust 2"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.